↓ Skip to main content

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing

Overview of attention for article published in Clinical Pharmacology & Therapeutics, May 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter
1 tweeter
wikipedia
1 Wikipedia page

Citations

dimensions_citation
166 Dimensions

Readers on

mendeley
156 Mendeley
Title
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing
Published in
Clinical Pharmacology & Therapeutics, May 2013
DOI 10.1038/clpt.2013.103
Pubmed ID
Authors

S G Leckband, J R Kelsoe, H M Dunnenberger, A L George, E Tran, R Berger, D J Müller, M Whirl-Carrillo, K E Caudle, M Pirmohamed

Abstract

Human leukocyte antigen B (HLA-B) is a gene that encodes a cell surface protein involved in presenting antigens to the immune system. The variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in response to carbamazepine treatment. We summarize evidence from the published literature supporting this association and provide recommendations for the use of carbamazepine based on HLA-B genotype (also available on PharmGKB: http://www.pharmgkb.org). The purpose of this article is to provide information to allow the interpretation of clinical HLA-B*15:02 genotype tests so that the results can be used to guide the use of carbamazepine. The guideline provides recommendations for the use of carbamazepine when HLA-B*15:02 genotype results are available. Detailed guidelines regarding the selection of alternative therapies, the use of phenotypic tests, when to conduct genotype testing, and cost-effectiveness analyses are beyond the scope of this document. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are published and updated periodically on the PharmGKB website at (http://www.pharmgkb.org).

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 156 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Hungary 1 <1%
Netherlands 1 <1%
Brazil 1 <1%
Sweden 1 <1%
United Kingdom 1 <1%
Japan 1 <1%
United States 1 <1%
Unknown 149 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 26 17%
Student > Master 21 13%
Researcher 19 12%
Student > Ph. D. Student 18 12%
Other 14 9%
Other 44 28%
Unknown 14 9%
Readers by discipline Count As %
Medicine and Dentistry 47 30%
Pharmacology, Toxicology and Pharmaceutical Science 25 16%
Biochemistry, Genetics and Molecular Biology 19 12%
Agricultural and Biological Sciences 19 12%
Unspecified 7 4%
Other 21 13%
Unknown 18 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 May 2017.
All research outputs
#2,456,760
of 9,792,785 outputs
Outputs from Clinical Pharmacology & Therapeutics
#542
of 1,961 outputs
Outputs of similar age
#67,446
of 249,761 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#10
of 32 outputs
Altmetric has tracked 9,792,785 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,961 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 249,761 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.